{
  "id": 8250212,
  "title": "ERK5 inhibition triggers CDK6 proteasomal degradation and enhances palbociclib efficacy in cancer cells",
  "url": "https://urgent.news/2026/09/18/erk5-inhibition-triggers-cdk6-proteasomal-degradation-and-enhances",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.17.752291v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Advanced endometrial cancer (EC) and melanoma are two malignancies with poor treatment options at advanced stages. CDK4 and CDK6 kinases play a central role in the regulation of cell proliferation by controlling progression through G1/S transition. CDK4/CDK6 inhibitors are currently in clinical trials for advanced ECs, whereas melanoma tumors frequently carry mutations affecting the CDK4/CDK6…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}